IL1B and cardiovascular disorder: While monoclonal antibodies targeting IL-1α and IL-1β have transformed the management of autoinflammatory, rheumatologic, and cardiovascular disease, their efficacy is often limited by poor tissue penetration, compensatory cytokine networks, and systemic immunosuppression risks.